SCHEMBL3794409

SCHEMBL3794409

Cc1ccc(N2CCN(C(=O)CCc3ccccc3)CC2)cc1C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 1/20 0.68
ME1 P48163 1/20 0.68
ME3 Q16798 1/20 0.68
MAPT P10636 4/20 0.67
KMT2A Q03164 3/20 0.67
MEN1 O00255 2/20 0.67
GFER P55789 1/20 0.67
ALDH1A1 P00352 4/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
AR P10275 1/20 0.57
NPC1 O15118 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
NPSR1 Q6W5P4 2/20 0.56
CYP2C19 P33261 1/20 0.56
HTT P42858 1/20 0.56
CNR1 P21554 1/20 0.56
CNR2 P34972 1/20 0.56
POLB P06746 2/20 0.55
FKBP1A P62942 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2820899 0.82 KMT2A (0.74) ME2ME1ME3MAPTKMT2A
SCHEMBL3799394 0.82 GFER (0.74) ME2ME1ME3MAPTKMT2A
SCHEMBL2821855 0.81 KMT2A (0.65) ME2ME1ME3MAPTKMT2A
SCHEMBL3797901 0.81 ME2 (1.00) ME2ME1ME3MAPTKMT2A
SCHEMBL8091444 0.81 MEN1 (0.80) ME2ME1ME3MAPTKMT2A
SCHEMBL2824683 0.80 MAPT (1.00) ME2ME1ME3MAPTKMT2A
SCHEMBL3796071 0.80 MAPT (0.80) ME2ME1ME3MAPTKMT2A
SCHEMBL3796501 0.80 MAPT (0.70) ME2ME1ME3MAPTKMT2A
SCHEMBL3799766 0.80 GFER (1.00) ME2ME1ME3MAPTKMT2A
SCHEMBL7131839 0.80 NPC1 (0.86) ME2ME1ME3MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160331-A1 NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND SK HOLDINGS CO. LTD. (KR) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160331-A1 NOVEL CARBAMOYLOXY ARYLALKAN ARYLPIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUND AND METHOD FOR TREATING PAIN, ANXIETY AND DEPRESSION BY ADMINISTERING THE COMPOUND HTR5A, OPRD1, OPRL1 ME2 3685/4885ME1 2926/4885ME3 3779/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.